2023
Prevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases.
Chan N, Einstein A, Griffin J, Rosenblum H, Teruya S, Cuomo M, De Los Santos J, DeLuca A, Johnson L, Kinkhabwala M, Leb J, Mintz A, Fine D, Helmke S, Muralidhar V, Pandey S, Sabogal N, Saith S, Winburn M, Smiley D, Miller E, Ruberg F, Maurer M. Prevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases. Journal Of Nuclear Cardiology 2023, 30: 2531-2539. PMID: 38245059, DOI: 10.1007/s12350-023-03310-7.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmyloidosisCardiomyopathiesDiphosphatesFemaleHumansMaleMiddle AgedPrevalenceTechnetiumTechnetium Tc 99m PyrophosphateTomography, X-Ray ComputedConceptsTc-99m PYP uptakeExtracardiac uptakeATTR-CACardiac amyloidosisClinically actionable findingsDiagnose transthyretin cardiac amyloidosisTc-99Transthyretin cardiac amyloidosisBone uptakeTime of scanningBreast uptakeTc-99m PYP imagingThyroid uptakeHeart failureBlack raceRenal uptakeNuclear imagingPyrophosphate imagingTechnetium pyrophosphateHispanic ethnicityHispanic participantsNuclear scintigraphyMinority populationsClinicSelf-identifyPrevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases
Chan N, Einstein A, Griffin J, Rosenblum H, Teruya S, Cuomo M, De Los Santos J, DeLuca A, Johnson L, Kinkhabwala M, Leb J, Mintz A, Fine D, Helmke S, Muralidhar V, Pandey S, Sabogal N, Saith S, Winburn M, Smiley D, Miller E, Ruberg F, Maurer M. Prevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases. Journal Of Nuclear Cardiology 2023, 30: 2531-2539. PMID: 37311914, DOI: 10.1007/s12350-023-03310-7.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmyloidosisCardiomyopathiesDiphosphatesFemaleHumansMaleMiddle AgedPrealbuminPrevalenceRadiopharmaceuticalsTechnetiumTechnetium Tc 99m PyrophosphateTomography, X-Ray ComputedConceptsExtracardiac uptakePYP uptakeCardiac amyloidosisBone uptakeActionable findingsTiming of scansTransthyretin cardiac amyloidosisHeart failureBreast uptakeMean ageBlack raceRenal uptakeHispanic ethnicityThyroid uptakeATTR-CANuclear scintigraphyHispanic participantsTechnetium pyrophosphateNuclear imagingPYP scanPopulation studiesSelf-identified BlackAdditional testingAmyloidosisSubjectsDiagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc99m pyrophosphate (PYP) imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis: the SCAN-MP study
Pandey S, Teruya S, Rodriguez C, Deluca A, Kinkhabwala M, Johnson L, Fine D, Sabogal N, Winburn M, Castillo M, Bhatia K, Malkovskaya R, Raiszadeh F, Kurian D, Miller E, Einstein A, Maurer M, Ruberg F. Diagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc99m pyrophosphate (PYP) imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis: the SCAN-MP study. Journal Of Nuclear Cardiology 2023, 30: 1414-1419. PMID: 36823486, PMCID: PMC11268194, DOI: 10.1007/s12350-023-03203-9.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmyloidosisCardiomyopathiesDiphosphatesHumansPrealbuminRadiopharmaceuticalsTechnetiumTechnetium Tc 99m PyrophosphateConceptsTransthyretin cardiac amyloidosisATTR-CACardiac amyloidosisLow pretest probabilityLow pretest likelihoodLV wall thicknessDiagnostic performance characteristicsPositive predictive valueNon-invasive diagnosisConclusionAmong patientsMinority older adultsHeart failurePretest likelihoodPretest probabilitySemi-quantitative parametersPYP uptakeImportant misclassificationPredictive valueImaging thresholdsOptimal heartOlder adultsDiagnostic performancePatientsReference standardScans
2022
Radiopharmaceutical supply disruptions and the use of 99mTc-hydroxymethylene diphosphonate as an alternative to 99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement
Miller EJ, Campisi R, Shah NR, McMahon S, Cuddy S, Gallegos-Kattan C, Maurer MS, Damy T, Slart RHJA, Bhatia K, Einstein AJ. Radiopharmaceutical supply disruptions and the use of 99mTc-hydroxymethylene diphosphonate as an alternative to 99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement. Journal Of Nuclear Cardiology 2022, 29: 2748-2760. PMID: 35838892, PMCID: PMC9285188, DOI: 10.1007/s12350-022-03059-5.Peer-Reviewed Original ResearchAmyloidosisCardiomyopathiesDiphosphatesDiphosphonatesHumansPrealbuminRadiopharmaceuticalsTechnetium Tc 99m Pyrophosphate
2021
Optimal interpretation of Tc99m PYP in 2020: Avoiding the million-dollar mistake
Gerber J, Miller EJ. Optimal interpretation of Tc99m PYP in 2020: Avoiding the million-dollar mistake. Journal Of Nuclear Cardiology 2021, 28: 503-506. PMID: 33442822, DOI: 10.1007/s12350-020-02503-8.Peer-Reviewed Original ResearchAmyloid Neuropathies, FamilialCardiomyopathiesHumansRadiopharmaceuticalsTechnetium Tc 99m PyrophosphateTomography, Emission-Computed, Single-Photon
2016
Can 99mTc-Pyrophosphate Aid in Early Detection of Cardiac Involvement in Asymptomatic Variant TTR Amyloidosis?
Haq M, Pawar S, Berk JL, Miller EJ, Ruberg FL. Can 99mTc-Pyrophosphate Aid in Early Detection of Cardiac Involvement in Asymptomatic Variant TTR Amyloidosis? JACC Cardiovascular Imaging 2016, 10: 713-714. PMID: 27568122, PMCID: PMC5318295, DOI: 10.1016/j.jcmg.2016.06.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAmyloid Neuropathies, FamilialAsymptomatic DiseasesCardiomyopathiesDisease ProgressionEarly DiagnosisFemaleGenetic Predisposition to DiseaseHeart FailureHumansMaleMiddle AgedMutationPhenotypePrealbuminPredictive Value of TestsRadionuclide ImagingRadiopharmaceuticalsTechnetium Tc 99m PyrophosphateNational patterns in imaging utilization for diagnosis of cardiac amyloidosis: A focus on Tc99m-pyrophosphate scintigraphy
Harb SC, Haq M, Flood K, Guerrieri A, Passerell W, Jaber WA, Miller EJ. National patterns in imaging utilization for diagnosis of cardiac amyloidosis: A focus on Tc99m-pyrophosphate scintigraphy. Journal Of Nuclear Cardiology 2016, 24: 1094-1097. PMID: 27016106, DOI: 10.1007/s12350-016-0478-3.Peer-Reviewed Original ResearchMeSH KeywordsAmyloid Neuropathies, FamilialCardiomyopathiesFemaleHumansMaleMiddle AgedPractice Patterns, Physicians'PrevalenceRadiopharmaceuticalsTechnetium Tc 99m PyrophosphateUnited StatesUtilization ReviewConceptsCardiac amyloidosisCA diagnosisContralateral lung ratioTransthyretin cardiac amyloidosisLung ratioDiagnostic modalitiesMost centersTest utilizationWeb-based surveyScintigraphyMultiple centersDiagnosisQuantification of uptakeLow penetranceNational surveyAmyloidosisNational patternsCardiologistsDose
2013
Nuclear Tracers for Transthyretin Cardiac Amyloidosis
Ruberg FL, Miller EJ. Nuclear Tracers for Transthyretin Cardiac Amyloidosis. Circulation Cardiovascular Imaging 2013, 6: 162-164. PMID: 23512778, DOI: 10.1161/circimaging.113.000178.Peer-Reviewed Original Research